TISIDB

Summary
Symbol	GRM3
Name	glutamate receptor, metabotropic 3
Aliases	GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location	7q21.1-q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Multi-pass membrane protein
Domain	PF00003 7 transmembrane sweet-taste receptor of 3 GCPR PF01094 Receptor family ligand binding region PF07562 Nine Cysteines Domain of family 3 GPCR
Function	G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling inhibits adenylate cyclase activity.

> Gene Ontology [ TOP ]
Biological Process	GO:0006140 regulation of nucleotide metabolic process GO:0006164 purine nucleotide biosynthetic process GO:0006171 cAMP biosynthetic process GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007193 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007194 negative regulation of adenylate cyclase activity GO:0007196 adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway GO:0007215 glutamate receptor signaling pathway GO:0007216 G-protein coupled glutamate receptor signaling pathway GO:0007270 neuron-neuron synaptic transmission GO:0009150 purine ribonucleotide metabolic process GO:0009152 purine ribonucleotide biosynthetic process GO:0009165 nucleotide biosynthetic process GO:0009187 cyclic nucleotide metabolic process GO:0009190 cyclic nucleotide biosynthetic process GO:0009260 ribonucleotide biosynthetic process GO:0030799 regulation of cyclic nucleotide metabolic process GO:0030800 negative regulation of cyclic nucleotide metabolic process GO:0030802 regulation of cyclic nucleotide biosynthetic process GO:0030803 negative regulation of cyclic nucleotide biosynthetic process GO:0030808 regulation of nucleotide biosynthetic process GO:0030809 negative regulation of nucleotide biosynthetic process GO:0030814 regulation of cAMP metabolic process GO:0030815 negative regulation of cAMP metabolic process GO:0030817 regulation of cAMP biosynthetic process GO:0030818 negative regulation of cAMP biosynthetic process GO:0031279 regulation of cyclase activity GO:0031280 negative regulation of cyclase activity GO:0035249 synaptic transmission, glutamatergic GO:0045761 regulation of adenylate cyclase activity GO:0045980 negative regulation of nucleotide metabolic process GO:0046058 cAMP metabolic process GO:0046390 ribose phosphate biosynthetic process GO:0050804 modulation of synaptic transmission GO:0051339 regulation of lyase activity GO:0051350 negative regulation of lyase activity GO:0051966 regulation of synaptic transmission, glutamatergic GO:0052652 cyclic purine nucleotide metabolic process GO:0072522 purine-containing compound biosynthetic process GO:1900371 regulation of purine nucleotide biosynthetic process GO:1900372 negative regulation of purine nucleotide biosynthetic process GO:1900542 regulation of purine nucleotide metabolic process GO:1900543 negative regulation of purine nucleotide metabolic process GO:1901293 nucleoside phosphate biosynthetic process
Molecular Function	GO:0001640 adenylate cyclase inhibiting G-protein coupled glutamate receptor activity GO:0001641 group II metabotropic glutamate receptor activity GO:0005246 calcium channel regulator activity GO:0008066 glutamate receptor activity GO:0016247 channel regulator activity GO:0098988 G-protein coupled glutamate receptor activity
Cellular Component	GO:0014069 postsynaptic density GO:0030424 axon GO:0030425 dendrite GO:0042734 presynaptic membrane GO:0043197 dendritic spine GO:0044309 neuron spine GO:0045211 postsynaptic membrane GO:0060076 excitatory synapse GO:0097060 synaptic membrane GO:0098793 presynapse GO:0098794 postsynapse GO:0099572 postsynaptic specialization

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04080 Neuroactive ligand-receptor interaction hsa04724 Glutamatergic synapse
Reactome	R-HSA-420499: Class C/3 (Metabotropic glutamate/pheromone receptors) R-HSA-418594: G alpha (i) signalling events R-HSA-388396: GPCR downstream signaling R-HSA-500792: GPCR ligand binding R-HSA-162582: Signal Transduction R-HSA-372790: Signaling by GPCR

Summary
Symbol	GRM3
Name	glutamate receptor, metabotropic 3
Aliases	GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location	7q21.1-q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between GRM3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	GRM3
Name	glutamate receptor, metabotropic 3
Aliases	GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location	7q21.1-q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of GRM3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	GRM3
Name	glutamate receptor, metabotropic 3
Aliases	GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location	7q21.1-q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of GRM3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.094	0.852
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.255	0.836
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.116	0.932
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0	1
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0	1
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0	1
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.066	0.865
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.066	0.912
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.395	0.216

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of GRM3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	37	11	26	0.00629
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	14.3	-14.3	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	37	10.2	26.8	0.00583
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	5.9	8.4	0.613
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	9.1	6.3	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	13.2	18.5	-5.3	0.729
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	23.1	-9.5	0.648
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	12.5	14.3	-1.8	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	0	9.1	0.458
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	16.7	0	16.7	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	GRM3
Name	glutamate receptor, metabotropic 3
Aliases	GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location	7q21.1-q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GRM3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	GRM3
Name	glutamate receptor, metabotropic 3
Aliases	GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location	7q21.1-q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GRM3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GRM3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	GRM3
Name	glutamate receptor, metabotropic 3
Aliases	GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location	7q21.1-q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GRM3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	GRM3
Name	glutamate receptor, metabotropic 3
Aliases	GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location	7q21.1-q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of GRM3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	GRM3
Name	glutamate receptor, metabotropic 3
Aliases	GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location	7q21.1-q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between GRM3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	GRM3
Name	glutamate receptor, metabotropic 3
Aliases	GPRC1C; mGlu3; MGLUR3; glutamate metabotropic receptor 3; Metabotropic glutamate receptor 3
Chromosomal Location	7q21.1-q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting GRM3 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting GRM3.

ID	Name	Drug Type	Targets	#Targets
DB05096	LY2140023	Small Molecule	GRM2, GRM3	2

Browse GRM3